Asthma is a common chronic inflammatory disease of the airways which remains uncontrolled despite current therapy for many patients. Asthma is characterised by fluctuating symptoms which include coughing, chest tightness, wheezing and shortness of breath. Genetic and environmental factors contribute to asthma and there are numerous stimuli that can trigger asthma, both atopic (allergic) and non-atopic (non-allergic).
Asthma has no cure, so long-term prevention focuses on avoiding known triggers. Asthma is classified by the frequency and extent of symptoms, the forced expiratory volume in one second (FEV1) and peak expiratory flow rate.
Treatment options for asthma include inhaled corticosteroids (ICS) which can be used alongside long-acting beta 2 agonists (LABA) or antileukotriene agents if the symptoms persist. Short-acting β2-agonist (SABA) as the only treatment is no longer recommended following strong evidence that this increases the risk of severe exacerbations and asthma-related death. Adding any ICS significantly reduces this risk.
To find out more about moderate to severe asthma, visit our dedicated Learning Zone, which contains further information on the causes of asthma and the Global Initiative for Asthma (GINA) recommendations for management.
Featured Learning Zones
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
GlaxoSmithKline plc and Innoviva, Inc. announced the FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD).
Novartis announced that high-dose, once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment.
Genentech, announced that the FDA accepted the company’s supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair (omalizumab) across all approved U.S. indications.
You may be interested in...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease. IPF is more common in elderly patients and over time as healthy lung tissue is replaced by altered extracellular matrix (fibrosis) the alveolar architecture is destroyed, leading to decreased lung function and finally respiratory failure and death.
ICRMB 2021: International Conference on Reproductive Medicine and Biology
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.